Tag: Large B-Cell Lymphoma

$Kite’s Yescarta Receives U.S. FDA Approval as First CAR T-cell Therapy for Initial Treatment of Relapsed or Refractory Large B-cell Lymphoma (LBCL)$

April 2, 2022 Off

Kite’s Yescarta Receives U.S. FDA Approval as First CAR T-cell Therapy for Initial Treatment of Relapsed or Refractory Large B-cell Lymphoma (LBCL)

By Author

Kite, a Gilead Company (Nasdaq: GILD), has announced the U.S. Food and Drug Administration (FDA) has approved Yescarta (axicabtagene ciloleucel) CAR T-cell therapy for adult patients with large B-cell lymphoma that is refractory to first-line chemoimmunotherapy or that relapses within 12 months of first-line chemoimmunotherapy.

$FDA accepts for priority review BMS’s Breyanzi as a second-line therapy for relapsed or refractory large B-cell lymphoma$

February 17, 2022 Off

FDA accepts for priority review BMS’s Breyanzi as a second-line therapy for relapsed or refractory large B-cell lymphoma

By Dino Mustafić

Bristol Myers Squibb (NYSE: BMY) has announced that the U.S. Food and Drug Administration (FDA) has accepted its supplemental Biologics…

February 20, 2019 Off

ADC Therapeutics doses patients in testing ADCT-402, after encouraging safety profile and anti-tumor activity

By Dino Mustafić

Oncology drug specialist ADC Therapeutics has continued with its Phase I clinical trial of combination of ADCT-402 (loncastuximab tesirine) with Pharmacyclics LLC’s ibrutinib, by dosing patients with advanced diffuse large B-cell lymphoma (DLBCL) or mantle cell lymphoma (MCL).